trending Market Intelligence /marketintelligence/en/news-insights/trending/OCC83FtafVIPVKXB9KwY2w2 content esgSubNav
In This List

Astellas, Pfizer's Xtandi extends lives of prostate cancer patients in study

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Astellas, Pfizer's Xtandi extends lives of prostate cancer patients in study

Japan's Astellas Pharma Inc. and U.S. pharmaceutical giant Pfizer Inc. said combining their cancer drug Xtandi with androgen deprivation therapy in a late-stage clinical study extended the life of patients while keeping the disease at bay.

The 1,150 patients in the study, named Arches, had prostate cancer that had spread to other parts of the body and was still responsive to medical or surgical treatment, a condition called metastatic hormone-sensitive prostate cancer.

In top-line results, the men who received both the drug and the therapy lived longer without disease worsening than those who received only the therapy. Androgen deprivation therapy depletes the body of the hormone that causes prostate cancer cells to grow.

Xtandi inhibits the receptors that accept the group of hormones known as androgens.

New York's Pfizer markets Xtandi in the U.S. with Astellas, which sells the drug in all other countries it is approved. In late October, the drug had its most recent regulatory win in Europe for men with high-risk, non-metastatic castration-resistant prostate cancer.